$Rigel Pharmaceuticals (RIGL.US)$ Rigel Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update Positive First-time full-year net income of $17.5M in 2024 Record net product sales of $144.9M, up 39% YoY Cash balance increased by $20M REZLIDHIA sales grew 118% to $23.0M TAVALISSE sales grew 12% to $104.8M Negative Higher costs and expenses at $155.1M vs $137.4M in 2023 Increased research and development costs in Q4
Jenna Ragan
OP
Day Lily
:
I'll take small amounts at 20%+ but I'm fully involved in most of these, I know what I'm hanging on to, so I'm waiting for more news and lots higher prices to sell all
NOTE! 1. NFA (Not Financial Advice!) 2. Do NOT open position WITHOUT chart confirmation, indicators, momentum. 3. Scale out and secure profits. 4. Most importantly, DON’T BLAME ME for your losses. Your trade, your accountability. 5. I DO NOT give buy or sell advice 6 COH (cash on hand); AH (after hours): RTH (regular trading hours); PR (press release; FCF (free cash flow) 7. NEVER be a blind follower. LASTLY, If you don’t a...
NOTE! 1. NFA (Not Financial Advice!) 2. Do NOT open position WITHOUT chart confirmation, indicators, momentum. 3. Scale out and secure profits. 4. Most importantly, DON’T BLAME ME for your losses. Your trade, your accountability. 5. I DO NOT give buy or sell advice 6 COH (cash on hand); AH (after hours): RTH (regular trading hours); PR (press release; FCF (free cash flow) 7. NE...
70761249
:
Can VERI make a breakthrough in the short term? The recent wildfires in Southern California are really heartbreaking, causing significant disappointment in the credibility of the media and government.
$Rigel Pharmaceuticals (RIGL.US)$ Rigel Announces R289 Granted Orphan Drug Designation by the FDA for MDS Thursday, 9th January at 8:05 am SOUTH SAN FRANCISCO, Calif., Jan. 9, 2025 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (NASDAQ: RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug designation to R289 for the treatment of myelodysplastic syndromes (MDS). R2891, ...
2
Report
No comment yet
Sign in to post a comment
Trending Stocks
Top Gaining Chinese Stocks Top Gaining Chinese Stocks
🎙️Discussion: 1. How will tariff policies affect the movement of key assets such as U.S. stocks, gold, and Bitcoin? 2. Given this context, Show More
Moo Live
Jan 23 16:54
MicroStrategy Q4 2024 earnings conference call
Reassessing Chinese Assets
Following the introduction of China's groundbreaking DeepSeek technology, Wall Street giants have revised their investment outlooks for the Chinese market.
Rigel Pharmaceuticals Stock Forum
Rigel Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
Positive
First-time full-year net income of $17.5M in 2024
Record net product sales of $144.9M, up 39% YoY
Cash balance increased by $20M
REZLIDHIA sales grew 118% to $23.0M
TAVALISSE sales grew 12% to $104.8M
Negative
Higher costs and expenses at $155.1M vs $137.4M in 2023
Increased research and development costs in Q4
21.+
and back to 20.+
1. NFA (Not Financial Advice!)
2. Do NOT open position WITHOUT chart confirmation, indicators, momentum.
3. Scale out and secure profits.
4. Most importantly, DON’T BLAME ME for your losses. Your trade, your accountability.
5. I DO NOT give buy or sell advice
6 COH (cash on hand); AH (after hours): RTH (regular trading hours); PR (press release; FCF (free cash flow)
7. NEVER be a blind follower.
LASTLY, If you don’t a...
1. NFA (Not Financial Advice!)
2. Do NOT open position WITHOUT chart confirmation, indicators, momentum.
3. Scale out and secure profits.
4. Most importantly, DON’T BLAME ME for your losses. Your trade, your accountability.
5. I DO NOT give buy or sell advice
6 COH (cash on hand); AH (after hours): RTH (regular trading hours); PR (press release; FCF (free cash flow)
7. NE...
WSJ· 08:36
Rigel Announces R289 Granted Orphan Drug Designation by the FDA for MDS
Thursday, 9th January at 8:05 am
SOUTH SAN FRANCISCO, Calif., Jan. 9, 2025 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (NASDAQ: RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug designation to R289 for the treatment of myelodysplastic syndromes (MDS). R2891, ...
No comment yet